a's cansino bio advances covid-19 vaccine into phase 2 on preliminary safety data
a's cansino bio advances covid-19 vaccine into phase 2 on preliminary safety data
in fact, virtual enrollment of the phase 2 study where interested individuals can sign up via a qr code has already started, putting cansino ahead of all the others on a long list of covid-19 vaccine developers.", "(cansino) in the global race to develop an effective vaccine to protect people against the novel coronavirus, chinas cansino bio has leapt ahead.", "cansino and its collaborators at the academy of military medical sciences institute of biotechnology plan to move their adenovirus type-5 vector-based recombinant covid-19 vaccine, ad5-ncov, into phase 2 clinical trial in china soon, the company said in a disclosure (pdf) to the hong kong stock exchange on thursday."


































)